There are 33 resources available
Pandemomics: Challenging assumptions in gynecologic oncology
Presenter: Michael Bookman
Session: Keynote address
Resources:
Slides
Webcast
Immunotherapy in cervical cancer: A paradigm shift
Presenter: Domenica Lorusso
Session: Is cervical cancer still an orphan disease?
Resources:
Slides
Webcast
Understanding the basics: Structure, key properties, mechanism of action, optimal diagnostic test to determine the target
Presenter: Kathleen Moore
Session: ADCs in gynaecological cancers
Resources:
Slides
Webcast
The evolving ADC treatment landscape in ovarian cancer
Presenter: Ilaria Colombo
Session: ADCs in gynaecological cancers
Resources:
Slides
Webcast
The new challenge: ADC class effects, on/off-target adverse reactions and their interdisciplinary management
Presenter: Toon Van Gorp
Session: ADCs in gynaecological cancers
Resources:
Slides
Webcast
The data absolutely support integration of HIPEC into primary ovarian cancer management (PRO)
Presenter: Willemien Van Driel
Session: How hot is HIPEC treatment in ovarian cancer?
Resources:
Slides
Webcast
HIPEC is not "IT" (CON)
Presenter: Leslie Randall
Session: How hot is HIPEC treatment in ovarian cancer?
Resources:
Slides
Webcast
Where are we now? Latest advances in treatment of gynecologic cancer
Presenter: Ana Oaknin
Session: GSK - Shifting the treatment paradigm of OC/EC: Towards a new horizon
Resources:
Webcast
Where are we going with OC? Evolving the management of 1L advanced ovarian cancer with PARPis
Presenter: Iain McNeish
Session: GSK - Shifting the treatment paradigm of OC/EC: Towards a new horizon
Resources:
Webcast
32O - 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the Phase III PAOLA-1/ENGOT-ov25 trial
Presenter: Domenica Lorusso
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast